Amgen Inc. (AMGN)
NASDAQ: AMGN · Real-Time Price · USD
298.24
+1.39 (0.47%)
At close: Jul 3, 2025, 1:00 PM
298.25
+0.01 (0.00%)
After-hours: Jul 3, 2025, 4:58 PM EDT
Amgen Revenue
Amgen had revenue of $8.15B in the quarter ending March 31, 2025, with 9.43% growth. This brings the company's revenue in the last twelve months to $34.13B, up 15.56% year-over-year. In the year 2024, Amgen had annual revenue of $33.42B with 18.57% growth.
Revenue (ttm)
$34.13B
Revenue Growth
+15.56%
P/S Ratio
4.70
Revenue / Employee
n/a
Employees
n/a
Market Cap
160.37B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 33.42B | 5.23B | 18.57% |
| Dec 31, 2023 | 28.19B | 1.87B | 7.09% |
| Dec 31, 2022 | 26.32B | 344.00M | 1.32% |
| Dec 31, 2021 | 25.98B | 555.00M | 2.18% |
| Dec 31, 2020 | 25.42B | 2.06B | 8.83% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
AMGN News
- 5 days ago - Amgen's gastric cancer drug meets late-stage trial goal - Reuters
- 5 days ago - AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER - PRNewsWire
- 11 days ago - Analyst Views Mixed As Amgen's Weight Loss/Diabetes Drug MariTide Shows Promise But Has Dose Issues - Benzinga
- 11 days ago - What's Happening With Amgen Stock? - Forbes
- 11 days ago - Amgen Inc. (AMGN) Presents at Special Call (IR Call) Conference Transcript - Seeking Alpha
- 12 days ago - Amgen Shares Fall on Weight-Loss Drug Tummy Troubles - Barrons
- 12 days ago - Low start dose of Amgen experimental weight-loss drug limits side effects - Reuters
- 12 days ago - RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS - PRNewsWire